Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation.
Uwe Klaus ZettlPaulus Stefan RommerOrhan AktasTorsten WagnerJoachim RichterPatrick OschmannLukas CepekBirte Elias-HampKlaus GehringAndrew ChanMichael HeckerPublished in: Expert review of clinical immunology (2023)
IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.